Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01055496 (Clinical Trial / inotuzumab ozogamycin / CMC-544)

Study Title
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin’s Lymphoma (NCT01055496)

Trial Description
This is a phase I trial designed to evaluate safety and tolerability of chemotherapy in combination with inotuzumab ozogamicin (CMC-544), an investigational product, in adults with CD22-positive non-Hodgkin’s lymphoma. The trial will involve two arms.

In one arm, subjects will receive chemotherapy regimen R-CVP (rituximab, cyclophosphamide, vincristine and prednisone). In the other arm, subjects will receive R-GDP (rituximab, gemcitabine, cisplatinum and dexamethasone). Subjects in both arms will also receive inotuzumab ozogamicin.

This trial is sponsored by UCB Pharma/Pfitzer. [1]

Study Data

Study Schematic 

NCT01055496 (Clinical Trial / inotuzumab ozogamycin / CMC-544)

Click here to Return to Drug map


Last Editorial review: July 31, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar